Biodesix (BDSX) Common Equity (2019 - 2026)

Biodesix (BDSX) has 8 years of Common Equity data on file, last reported at $9.1 million in Q1 2026.

• Quarterly Common Equity fell 17.43% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 17.43% YoY) and the FY2025 annual result came in at -$2.5 million, down 111.81% from the prior year.
• Common Equity improved to $9.1 million in Q1 2026, from -$2.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $36.3 million in Q2 2024 to a low of -$7.0 million in Q2 2023.
• A 5-year average of $7.7 million and a median of $4.6 million in 2023 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 2026.49% in 2024, down 220.92% in 2024.
• Tracing BDSX's Common Equity over 5 years: stood at $20.6 million in 2022, then sank by 77.77% to $4.6 million in 2023, then soared by 355.81% to $20.9 million in 2024, then tumbled by 111.81% to -$2.5 million in 2025, then soared by 470.47% to $9.1 million in 2026.
• The last three Common Equity figures came in at $9.1 million (Q1 2026), -$2.5 million (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.